The human skeleton is a complex organ that forms during embryogenesis, grows during childhood, remodels throughout adult life, and regenerates following injury. The spatial boundaries of its temporal existence are exquisitely regulated. Extraskeletal or heterotopic ossification (HO) occurs sporadically or in several rare, but illustrative genetic disorders^[@R1]^. As in normal skeletal morphogenesis, HO can form through either an intramembranous or endochondral process, suggesting that multiple mechanisms are involved ^[@R1]^. The cellular defect lies in aberrant cell-fate determination of mesenchymal progenitor cells in soft tissues, resulting in inappropriate formation of chondrocytes or osteoblasts, or both. HO is illustrated by two rare genetic disorders that are clinically characterized by extensive and progressive extraskeletal bone formation: fibrodysplasia ossificans progressiva (FOP) and progressive osseous heteroplasia (POH). In FOP (OMIM\#135100), activating mutations in activin receptor type-1, a bone morphogenetic protein type I receptor, induce HO through endochondral ossification^[@R2]^. Ectopic BMP signaling induces ectopic chondrocyte differentiation prior to bone formation and HO is preceded by ectopic cartilage formation in FOP^[@R3]^. In POH (OMIM\#166350) and Albright hereditary osteodystrophy (AHO, OMIM\#103580), however, HO occurs predominantly through an intramembranous process^[@R4],[@R5]^ and ectopic osteoblasts differentiate from mesenchymal progenitors independently of chondrocytes in these disorders. Clinically, POH presents during infancy with dermal and subcutaneous ossifications that progress during childhood into skeletal muscle and deep connective tissues (e.g. tendon, ligaments, fascia). Over time, ectopic ossifications lead to ankylosis of affected joints and growth retardation of affected limbs. By contrast, ectopic bone in AHO presents later in life and is largely restricted to cutaneous and subcutaneous tissue^[@R6]^. POH and AHO are caused by inactivating mutations in *GNAS*^[@R4],[@R5],[@R7],[@R8]^, which encodes Gα~s~ that transduces signals from G protein coupled receptors (GPCRs). However, unlike FOP, the molecular mechanism underlying POH and AHO remains unknown as the connection between Gα~s~ and a signaling pathway that is both necessary and sufficient to control intramembranous ossification has not been determined.

Gα~s~ has emerged as a seminal regulator of mesenchymal progenitors in the skeletal system. Activating mutations in *GNAS* cause fibrous dysplasia (FD) (OMIM\# 174800), in which osteoblast differentiation from mesenchymal progenitors is impaired^[@R9]^. We have found previously that activated Gα proteins are playing important roles during skeletal development and in disease by modulating Wnt/β-catenin signaling strength^[@R10]^. The activating *GNAS* mutations that cause FD potentiate Wnt/β-catenin signaling, and activation of Wnt/β-catenin signaling in osteoblast progenitors results in an FD-like phenotype^[@R10]^. It is intriguing that POH or AHO does not mirror FD phenotypically or molecularly. Removal of *Gnas* in mice weakened Wnt/β-catenin signaling and commitment of mesenchymal progenitors to the osteoblast lineage and bone formation^[@R10],[@R11]^. Therefore, weak Wnt/β-catenin signaling due to *GNAS* inactivation cannot be the cause of POH or AHO.

Gα~s~ is a physiological activator of PKA, an inhibitor of Hh signaling that governs a wide variety of processes during development^[@R12]-[@R14]^. However, Hh signaling has not been found to be required for intramembranous ossification as occurs in POH^[@R15]^. In addition, a causal link between Gα~s~ and Hh signaling has never been established in any genetic system^[@R16]-[@R18]^. Furthermore, although activated Gα~i~ has been implicated in promoting Hh signaling activity in *Drosophila*^[@R19]^, it is neither sufficient nor necessary for Hh signaling at least in vertebrates^[@R20],[@R21]^.

Trauma-associated non-hereditary HO is a common complication in adults^[@R22]^, which represents a major unresolved medical challenge. Genetic forms of HO provide the opportunity to identify the molecular mechanisms whereby bone formation is spatially restricted. We therefore investigated which molecular pathway(s) regulated by Gα~s~ induces ectopic osteoblast differentiation in animal models of POH.

Results {#S1}
=======

Loss of *Gnas* leads to POH-like skeletal anomalies {#S2}
---------------------------------------------------

Unlike the POH patients, heterozygous loss of *Gnas* function in *Gnas^+/−^* mice only caused osteoma cutis late in life, a cutaneous condition characterized by the presence of bone within the skin, through an unknown mechanism^[@R23],[@R24]^. Because HO in the *Gnas^+/−^* mice lacks the two critical POH features of early onset and progressive invasion into deep tissues, we hypothesized that a further reduction of *Gnas* was required. Therefore, we completely removed *Gnas* in limb mesenchymal progenitor cells using the *Prx1-Cre* line. While the *Prx1-Cre; Gnas^f/+^* mice appeared normal, homozygous loss of *Gα~s~* in the *Prx1-Cre; Gnas^f/−^* or *Prx1-Cre; Gnas^f/f^* mice resulted in numerous skeletal anomalies as well as severe and progressive HO resembling the phenotypes of POH ([Fig. 1](#F1){ref-type="fig"}). *Gα~s~* was efficiently removed in the limbs, but not in the axial tissue by *Prx1-Cre* at E14.5 as assayed by mRNA expression, gene deletion in the genome and protein levels ([Supplemental Fig. 1a--c](#SD1){ref-type="supplementary-material"}). The *Prx1-Cre; Gnas^f/−^* and the *Prx1-Cre; Gnas^f/f^* mice showed similar phenotypes and were born with soft tissue syndactyly (webbing between the digits), fused joints and progressive HO in soft tissues ([Fig. 1](#F1){ref-type="fig"}). Extra-skeletal mineralization was first detected between embryonic day (E) 16.5 and 17.5, accelerated perinatally, and was extensive by postnatal day 4 (P4). HO was noted in the interdigital regions and between radius and ulna, which resulted in bone fusions by P4 ([Fig. 1a,b](#F1){ref-type="fig"}). Progressive mineralization continued to P20 when most mutant pups died with extensive bone and joint fusions and tendon mineralization ([Fig. 1c,d](#F1){ref-type="fig"}). Similar HO phenotypes were also observed when *Gnas* was removed using either the *Dermo1-Cre* or *Ap2-Cre*, which excises more broadly in mesenchymal tissues outside of the limb ([Supplementary Fig. 2a,b](#SD1){ref-type="supplementary-material"}). Therefore, *Gnas* is required in multiple mesenchymal tissues to suppress ectopic mineralization.

To demonstrate that the ectopic mineralization is associated with osteoblast differentiation during ossification, Von Kossa staining and immunohistochemistry of early osteoblast marker Osterix (Osx)^[@R25]^ and mature osteoblast marker osteocalcin (Oc) was performed ([Fig. 1e,f](#F1){ref-type="fig"} **and** [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). In P4 mutant limbs, Von Kossa staining confirmed the presence of extensive mineralization in the *Prx1-Cre;Gnas^f/f^* mice ([Fig. 1e](#F1){ref-type="fig"}). Osx-positive and Oc-positive cells were detected in the ectopic bone tissues, in both subcutaneous and interdigital regions, where ectopic cartilage was not found ([Fig. 1f](#F1){ref-type="fig"} **and** [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). These data demonstrate that loss of *Gnas* in mesenchymal progenitor cells induce ectopic osteoblast differentiation through a progressive non-cartilaginous intramembranous bone formation process. The *Prx1-Cre;Gnas^f/−^* or *Prx1-Cre;Gnas^f/f^* mouse is a mouse model of POH that allows us to investigate the molecular and cellular mechanism of *Gnas* in restricting bone formation.

Loss of *Gnas* promotes ectopic osteoblast differentiation {#S3}
----------------------------------------------------------

Because HO often occurs in adults^[@R22]^, we determined if loss of *Gnas* in adult subcutaneous mesenchymal tissues could also lead to HO. We injected Cre- or GFP-containing adenoviruses (Ad-Cre or Ad-GFP) subcutaneously into 4 week old *Gnas^f/f^* mice ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Extensive HO was detected 6 weeks post injection by the presence of ectopic osteoblasts and mineralization in the Ad-Cre, but not the Ad-GFP, injected dermal and subcutaneous regions ([Fig. 2a,b](#F2){ref-type="fig"}), demonstrating that loss of *Gnas* in adult subcutaneous mesenchymal tissues is sufficient to cause HO similar to that found in POH and AHO. Importantly, as has been found in POH patients, such induced HO was progressively more severe and invaded deep muscular tissues when more time was allowed for HO to develop ([Fig. 2c,d](#F2){ref-type="fig"})

To test whether HO results from ectopic osteoblast differentiation of mesenchymal progenitors cells, We isolated bone marrow stromal cells (BMSCs) and subcutaneous mesenchymal progenitors (SMP) from the *Gnas^f/f^* mice and infected them with Ad-Cre to remove *Gnas*. Efficient *Gnas* deletion was observed ([Supplemental Fig. 1d--f](#SD1){ref-type="supplementary-material"}). Ad-Cre-infected BMSCs ([Fig. 3a,b](#F3){ref-type="fig"}) and SMPs ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}) showed accelerated osteogenic differentiation as demonstrated by enhanced mineralized matrix formation. This was confirmed by stronger expression of osteoblast differentiation markers such as *Osx*, *Collagen 1a1 (Col1a1)*, *Alkaline Phosphatase (Alpl)*, *Bone Sialoprotein (BSP)* and *Osteocalcin (Oc)* in Ad-Cre-infected BMSCs compared to Ad-GFP-infected BMSCs ([Fig. 3c](#F3){ref-type="fig"}).

*Gnas* is required to inhibit Hh signaling {#S4}
------------------------------------------

We have found previously that the activating *GNAS* mutations causing FD potentiate Wnt/β-catenin signaling^[@R10]^. As low Wnt/β-catenin signaling does not permit osteoblast differentiation^[@R26]-[@R29]^, it is unlikely that *GNAS* inactivation causes ectopic bone formation in POH or AHO by reducing the already low Wnt/β-catenin signaling in soft tissue mesenchymal progenitor cells. To test whether Gα~s~ may also regulate bone formation by regulating Hh signaling, we asked first whether Gα~s~ is a major regulator of PKA that controls Hh signaling activity *in vitro* and *in vivo*.

We found that *in vitro*, loss of *Gnas* in SMPs and BMSCs leads to weaker Wnt signaling indicated by lower expression of Wnt/β-catenin target genes *Axin2*, *Tcf1* and *Lef1*; and β-catenin protein levels^[@R30]^ ([Supplementary Fig. 4b--d](#SD1){ref-type="supplementary-material"}). While cAMP levels and PKA activities (assayed by Creb phosphorylation) were also lower, Hh signaling was higher as indicated by expression of Hh target genes *Patched 1(Ptch1), Gli1* and *Hh interacting protein (Hhip)* ([Fig. 4a--c](#F4){ref-type="fig"}, [Supplemental Fig. 4e,f](#SD1){ref-type="supplementary-material"}). Blocking cAMP degradation with IBMX^[@R31]^, or activating cAMP production with forskolin^[@R32]^ rescued the effects caused by *Gnas* removal ([Fig. 4d--f](#F4){ref-type="fig"}). Furthermore, expression of a dominant negative form of *PKA* (dnPKA) mimicked the effects of *Gnas* removal ([Fig. 4g--j](#F4){ref-type="fig"}). *In vivo,* while Wnt/β-catenin target gene expression and β-catenin protein levels were lower ([Supplementary Fig. 5a,b](#SD1){ref-type="supplementary-material"}), expression of *Ptch1, Gli1* and *Hhip* was higher in the *Prx1-Cre;Gnas^f/−^* limb at E14.5, including in the interdigital areas, prior to HO appearance at E17.5 ([Fig. 3d--f](#F3){ref-type="fig"}). Regulation of Hh signaling by *Gnas* was further confirmed by strong genetic interactions between *Gnas* and *Ptch1* ([Supplementary Fig. 5c--g](#SD1){ref-type="supplementary-material"}). Ptch1 is an inhibitor of the Hh pathway and the *Ptch1^+/−^* mice provide a sensitized genetic background to test other suppressors of Hh signaling^[@R33]^. *Ptch1* heterozygosity enhanced the phenotypes caused by *Dermo1-Cre* or *Ap2-Cre* induced *Gnas* removal ([Supplementary Fig. 5c--g](#SD1){ref-type="supplementary-material"}), indicating that an important *in vivo* function of *Gnas* is to suppress Hh signaling. This was further tested in the developing neural tube where the Hh signaling gradient patterns the dorsal-ventral axis^[@R34]^. In the *Gnas^−/−^* embryos that died at E9.5, Hh target gene expression was higher, while Wnt target gene expression was lower, and the neural tube was ventralized ([Supplementary Fig. 6a--c](#SD1){ref-type="supplementary-material"}). These defects phenocopied the mutant embryos due to loss of Hh signaling inhibitors such as *PKA*, *Ptch1* and *suppressor of fused* (*Sufu*)^[@R13],[@R33],[@R35]^. In contrast, inhibiting Gα~i~ family members had no effect on limb patterning, skeletal development or Hh signaling activity ([Supplementary Fig. 6d,e](#SD1){ref-type="supplementary-material"}). Thus, Gα~s,~ but not Gα~i,~ is a required important *in vivo* regulator of Hh signaling in multiple tissues and at multiple stages of development.

Hh exerts its biological activity by altering the balance between activator (full length) and repressor (truncated) forms of the Gli family of zinc-finger transcription factors (Gli^A^ and Gli^R^)^[@R36]^. Increased Gli^A^ and reduced Gli^R^ indicate Hh pathway activation^[@R37]^. In vertebrates, Gli^R^ function is largely derived from Gli3, while the primary Gli^A^ activity is largely from Gli2. Expression of Hh target genes requires Gli^A^ function. As PKA regulates both Gli3 processing and Gli2 activation^[@R13],[@R38],[@R39]^, we tested whether Gα~s~ acts through PKA to regulated Hh signaling by performing limb culture experiments. While a PKA inhibitor, H89, upregulated Hh target gene expression in the wild type limb ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}), forskolin potently suppressed elevated Hh signaling in the mutant limb ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}). Since Gli2 is required for ventral neural tube patterning^[@R40],[@R41]^, expansion of the ventral-most neural tube marker expression in the *Gnas^−/−^* embryos ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}) indicated that Gli2 is activated by loss of *Gnas*. In addition, the full length Gli3 (Gli3^A^) and Gli2 levels were higher and Gli3^R^ levels were lower in the *Prx1-Cre;Gnas^f/−^* limb bud relative to littermate controls ([Supplementary Fig. 7c,d](#SD1){ref-type="supplementary-material"}). Taken together, our data indicate that Gα~s~ suppresses Hh signaling by regulating Gli activation and processing through PKA. Consistent with this, we found that cyclopamine, an inhibitor of the Hh receptor Smoothened (Smo)^[@R42]^, could not suppress Hh target gene expression in the *Gnas* deficient limb, while Gli inhibitors, arsenic trioxide (ATO)^[@R43]^ or GANT58^[@R44]^ could ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}). These results indicate that Gα~s~ acts downstream of Smo and upstream of Gli transcription factors to suppress Hh signaling in embryonic limbs.

Active Hh signaling is necessary and sufficient to cause HO {#S5}
-----------------------------------------------------------

Gli2 mainly forms Gli^A^ that transduces Hh signaling^[@R45],[@R46]^. To test whether activated Hh signaling plays an essential role in inducing HO, we removed *Gli2* in the *Gnas* mutant mice. Loss of a single copy of *Gli2* led to a partial amelioration of HO in the limbs of the *Prx1-Cre;Gnas^f/−^* mice ([Fig. 5a](#F5){ref-type="fig"}). Loss of both copies of *Gli2* further ameliorated ectopic mineralization, particularly in the hindlimb, where the mutant phenotypes of HO, syndactyly, and joint fusion were almost completely rescued ([Fig. 5a](#F5){ref-type="fig"}). Amelioration of HO was also achieved by injecting pharmacologic inhibitors of Gli, ATO or GANT58, into female mice pregnant with the *Prx1-Cre;Gnas^f/−^* pups ([Fig. 5b](#F5){ref-type="fig"}). While higher and more frequent doses of these compounds are required to inhibit Hh-driven tumor growth in adult mice^[@R43],[@R44]^, similar dosing in pregnant female mice led to spontaneous abortion, precluding their use in this model. Inhibition of osteoblast differentiation by GANT-58 was also observed *in vitro* in the *Gnas-*deficient BMSCs ([Fig. 5c](#F5){ref-type="fig"} **and** [Supplementary Fig. 7e](#SD1){ref-type="supplementary-material"}). Taken together, these data demonstrate that Hh signaling activation is required for osteoblast differentiation driven by loss of *Gnas* function in mesenchymal progenitors.

To test whether HH signaling is indeed upregulated in POH patients, we performed GLI1 and GLI2 immunohistochemistry on HO samples from two POH individuals^[@R7]^. GLI1 and GLI2 expression was present in hair follicles where Hh signaling is active under normal conditions ([Supplementary Fig. 7f,g](#SD1){ref-type="supplementary-material"}). In the POH samples, GLI1 and GLI2 expression was also detected in cells within the ectopic bone tissue ([Fig. 6c](#F6){ref-type="fig"}, [Supplementary Fig. 7g](#SD1){ref-type="supplementary-material"}). The most intense detection of GLI1 and GLI2 was along the surface of the ectopic bone, suggesting that Hh signaling is most highly upregulated at the leading edge of new bone formation that contains bone forming progenitor cells. This is consistent with our *in vitro* data showing that Hh signaling is highly upregulated in progenitor cells just prior to osteoblastic differentiation ([Fig. 3f](#F3){ref-type="fig"}). In the limb of the *Prx1Cre; Gnas^f/f^* mouse at P4, loss of *Gnas* led to upregulated Gli1 protein in most cells compared to the wild type control ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). We also found that areas of adipose tissue appeared to contain occasional GLI1 positive cells ([Fig. 6c](#F6){ref-type="fig"}), suggesting these cells are potential osteoprogenitor cells within the subcutaneous fat tissue. These findings support that upregulated HH signaling also drives ectopic bone formation in the human disease.

To test whether Hh signaling activation alone is sufficient to cause HO, Ad-Cre was injected subcutaneously into the limbs of the adult *R26SmoM2* mice^[@R47]^, in which an activated form of *Smo* (*SmoM2*) is expressed following Cre-mediated recombination. Eight weeks after Ad-Cre injection, but not Ad-GFP injection, HO was readily detected ([Fig. 6d](#F6){ref-type="fig"}). BMSCs and SMPs from the *R26SmoM2* mice also showed upregulated Hh signaling and accelerated osteoblast differentiation after Ad-Cre infection ([Fig. 6e](#F6){ref-type="fig"} **and** [Supplementary Fig. 8b--d](#SD1){ref-type="supplementary-material"}). These results demonstrate that Hh signaling activation is both necessary and sufficient to induce HO, and that Hh signaling must be actively suppressed by Gα~s~ to ensure spatial restriction of bone formation to the normal skeleton.

Discussion {#S6}
==========

Here we show that loss of *Gnas* causes HO by activating Hh signaling. Further, we provide evidence that previously identified Hh signaling inhibitors, particularly Gli inhibitors that have been developed for cancer therapy, may be repurposed to treat HO and possibly other diseases caused by reduction of Gα~s~ activity. This work together with our previous study^[@R10]^ provide deep mechanistic insights into how gain of function and loss of function mutations of the same *GNAS* gene cause completely different diseases (FD vs. POH) by identifying distinct downstream pathways (Wnt/β-catenin and Hh) that primarily mediate the effects of activated or inactivated Gα~s~ signaling respectively. As both high and low Gα~s~ signaling causes bone diseases, our work highlights the necessity and significance of tightly regulating Gα~s~ activities by GPCRs both spatially and temporally. Due to the large number of GPCRs and their ligands, it would not be surprising that mutations disrupting a GPCR or the production of one class of GPCR ligands result in less pronounced alteration in Hh or Wnt signaling and therefore less severe phenotypes. Consistent with this, it has been found that loss of a GPCR, Gpr161 that has no known ligand, causes milder developmental defects in mouse embryos^[@R48]^ compared to the *Gnas^−/−^* mutant shown here.

As a critical regulator of osteoblast differentiation from mesenchymal progenitor cells, Gα~s~ exerts its function by modulating the signaling activities of Wnt/β-catenin and Hh, both of which are key signaling pathways that play fundamental roles in skeletal development and disease^[@R49]^. Activation or inactivation of *GNAS* causes upregulation of only one of the two pathways, indicating that one function of Gα~s~ in mesenchymal progenitor cells is to maintain a critical balance between Wnt/β-catenin and Hh signaling, which is required for osteogenesis and its spatial regulation. Only appropriate levels of Hh and Wnt signaling determined by a specific range of Gα~s~ activities (shown by the box in [Fig.6f](#F6){ref-type="fig"}) result in normal bone formation. Outside the boxed range, extreme Wnt or Hh signaling either inhibits bone formation in the skeleton or causes ectopic bone formation in soft tissues. Therefore, it is likely that distinct mutations in *Gnas* cause corresponding bone diseases such as FD and POH by altering the balance to enhance either Wnt/β-catenin or Hh signaling, respectively ([Fig. 6f](#F6){ref-type="fig"}).

Genetic studies showed that Wnt signaling acts permissively for osteoblast differentiation. Osteoblast differentiation is favored when Wnt signaling is above a threshold level^[@R26]-[@R28],[@R50],[@R51]^. Therefore, Wnt signaling alteration itself primarily affects bone formation in the normotopic skeleton and cannot cause ectopic bone formation unless an inducer(s) of osteoblast differentiation is present. Here we identify that one such inducer is Hh signaling. In the POH mouse model, lower Wnt signaling was not sufficient to inhibit ectopic bone formation promoted by ectopic Hh signaling. It is important to note that over-activated Wnt signaling also inhibits osteoblast differentiation^[@R10],[@R52]-[@R56]^. This together with lower HH signaling explains the phenotype of FD. As both Wnt and Hh signaling pathways have potent regulatory activities, certain reduction of their normal signaling levels can be tolerated, whereas ectopic signaling causes deleterious effects. Therefore, the disease phenotypes at the tissue and cellular levels are primarily determined by the pathway that is activated. As Wnt and Hh signaling is both required to regulate a diverse array of developmental and physiological processes, our finding that their balance is regulated by *Gnas* provides an important conceptual framework to understand the molecular and cellular mechanisms of skeletal and possibly other diseases.

Our studies show that ectopic bone in soft tissues forms by differentiation of osteoblast cells from mesenchymal progenitor cells. Even when *Gnas* is removed uniformly in early limb buds, as in the *Prx1Cre; Gnas^f/−^* mouse, HO that occurs later still progresses from the distal limb ([Fig. 1](#F1){ref-type="fig"}), which contains more progenitor cells than the proximal limb^[@R57],[@R58]^. Hh ligand-mediated Hh signaling is only required for endochondral bone formation^[@R15]^, raising the possibility that intramembranous bone formation in the skull may be promoted by ligand-independent activation of Hh signaling. Our finding that Hh signaling activation due to loss of Gα~s~ signaling is both necessary and sufficient for HO through the intramembranous mechanism suggests that this signaling crosstalk may also be important in physiological bone formation and homeostasis. For instance, defective GPCR-Gα~s~ signaling may cause impaired development of cranial and clavicle bones. Furthermore, it would be interesting to determine whether the appearance of extra-skeletal dermal bone, which is physiologically important in some species, for example, the armadillo, is caused by alteration in the GPCR-Gα~s~-Hh signaling axis during evolution.

The mosaic nature of HO in POH and AHO suggests that the mild elevation of basal Hh signaling in these patients provides a sensitized tissue background for ectopic osteoblast differentiation that occurs when additional Hh signaling or other osteogenic factors are provided by a local microenvironment. For instance, elevated Hh signaling in the hair follicle may trigger HO in the subcutaneous region observed in POH and AHO patients. Non-hereditary forms of HO often contain a mixture of both cartilage and bone. It is possible that the underlying molecular mechanisms of non-hereditary forms of HO are a combination of those underlying POH and FOP. In fact, the developmental program of ectopic chondrogenesis orchestrated by dysregulated BMP signaling also upregulates Hh signaling at ectopic sites^[@R59]^. Therefore, a combination of Hh inhibitors and the nuclear retinoic acid receptor-γ agonists^[@R60]^, which block chondrogenesis, may be a promising strategy to treat POH as well as common, non-hereditary forms of HO.

Online Methods {#S8}
==============

Mice {#S9}
----

All mouse experiments were approved by the NIH IACUC. All mice have been previously described in the literature: *Gα~s~^f/f^*^[@R61]^, *Prx1-Cre*^[@R62]^, *Dermo1-Cre*^[@R63]^, *Ap2-Cre*^[@R64]^, *Ptch1^f/f^*^[@R65]^, *Gli2^−/−^*^[@R66]^, *Gli2^f/f^*^[@R67]^, *Smo^f/f^*^[@R68]^, *R26SmoM2*^[@R69]^, *Rosa26-PTX*^[@R70]^ and *Gnaz^−/−^*^[@R71]^. All animal experiments were performed under a protocol approved by the NHGRI Animal Care and Use Committee.

Human samples {#S10}
-------------

Collection of POH patient samples was approved by the Institutional Review Board of the University of Pennsylvania. Informed consent was obtained from all subjects.

Skeletal preparation (alizarin red-alcian blue staining) {#S11}
--------------------------------------------------------

Embryos were skinned and placed in 100% EtOH overnight. Embryos were then placed in staining solution for 2 days and processed according to (50 mL staining solution= 2.5 mL 0.3% alcian blue, 2.5 mL 0.1% alizarin red, 2.5 mL 100% glacial acetic acid, 42.5 mL 70% EtOH). Rinsed embryos with water then placed in 1% KOH until destained. Placed embryos in 80% glycerol for storage.

Von Kossa and alizarin red staining {#S12}
-----------------------------------

Tissue sections were deparaffinized and hydrated in distilled H~2~O. We added 5% silver hydrate to slides and then placed them under a 60-watt lamp for 1 hour. Slides were rinsed three times in distilled water. 5% sodium thiosulfate was added to slides for 5 minutes. We rinsed slides three times in distilled water. We counterstained slides with nuclear fast red for 5 minutes. We then rinsed slides three times in distilled water. Slides were dehydrated and cleared in xylene before mounting with Permont. For Von Kossa staining of cell cultures, We fixed the cells in 2.5% gluteraldehyde in PBS for 2 hours, washed them in distilled water, and then stained them with 5% silver nitrate under a 60 watt lamp for 1 hr. We washed the stained cells in distilled water 3 times, then in 5% sodium thiosulfate for 5 min, and then rinsed them in water. For alizarin red staining of cell cultures, We rinsed cells with PBS and fixed them with 4% PFA for one hour at room temperature. After washing them with water, we stained them with freshly made alizarin red staining solution (1% alizarin red in 2% Ethanol) for 5 minutes before we washed them five times with distilled water.

Immunohistochemistry {#S13}
--------------------

We deparaffinized and then hydrated tissue sections. We then placed slides into boiling 10mM citrate pH6 for 15 minutes and room temperature for 15 minutes. We placed slides in 3%H~2~O~2~/MeOH for 15 minutes, equilibrated slides in phosphate buffered saline with 0.1% Tween-20 (PBS-T), blocked them for 1 hour with 5% normal goal serum in PBS-T and applied rabbit anti-Osx antibody (Abcam; ab22552) at 1:1000. We washed slides and detected signal using the anti-rabbit ABC elite kit (Vector labs; PK-6101) and DAB tablets (Sigma-Aldrich; D4293). We counterstained slides with nuclear fast red and alcian blue then dehydrated, cleared them with xylene and mounted them with Permont. For GLI1 immunohistochemistry, following incubation with 1:100 GLI1 antibody (Santa Cruz Biotechnology) overnight at 4°C, sections were incubated with universal secondary antibody (Broad Spectrum, Zymed Laboratories) for 25 min, 50 °C , then blocked (Background Buster; American MasterTech) for 30 min and hydrogen peroxide blocking reagent (Lab Vision Corp.) for 15 min, both at room temperature. Sections were incubated with streptavidin-HRP (Open Biosystem) for 30 min at 50 °C and color development used DAB (*SuperPicTure*™ Polymer, Invitrogen) for 5 min at 37°C. Adult tissue sections for specific protein immunohistochemistry were counterstained with Mastertech Harris Hematoxylin and Nuclear Fast Red was used as a counterstain for Von Kossa staining. Neonatal tissue sections were counterstained with Alcian blue, followed by Sirius red.

qRT-PCR {#S14}
-------

We isolated the total RNA first with Trizol (Invitrogen) and then with the RNeasy Kit (Qiagen) with on column DNAse digestion. We generated 1^st^ strand cDNA using the iScript cDNA Synthesis Kit (BioRad). qPCR was performed using an ABI7900 light cycler and 40 cycles of 95°C 15 seconds and 60°C for 60 seconds. PCR product accumulation was detected using Sybr green (Invitrogen; Platimun SYBR Green qPCR SuperMix-UDG). Primers used for amplification are Actin: Forward 5′-CAC AGC TTC TTT GCA GCT CCT T-3′, Reverse 5′-CGT CAT CCA TGG CGA ACT G-3′; Tubulin: Forward 5′- CAA CGT CAA GAC GGC CGT GTG-3′, Reverse 5′-GAC AGA GGC AAA CTG AGC ACC-3′; Gα~s~: Forward 5′-GCA GAA GGA CAA GCA GGT CT-3′, Reverse 5′-CCC TCT CCG TTA AAC CCA TT-3′; Ptch1: Forward 5′-CTC TGG AGC AGA TTT CCA AGG-3′, Reverse 5′-TGC CGC AGT TCT TTT GAA TG-3′; Gli1: Forward 5′-GAA AGT CCT ATT CAC GCC TTG A-3′, Reverse 5′-CAA CCT TCT TGC TCA CAC ATG TAA G-3′; Hhip: Forward 5′-GGG AAA AAC AGG TCA TCA GC-3′, Reverse 5′-ATC CAC CAA CCA AAG GGC-3′. Osx: Forward 5′- CCC ACT GGC TCC TCG GTT CTC TCC -3′, Reverse 5′- GCTBGAA AGG TCA GCG TAT GGC TTC -3′; Col1a1: Forward 5′- CAC CCT CAA GAG CCT GAG TC -3′, Reverse 5′- GTT CGG GCT GAT GTA CCA GT -3′; Alk Phos: Forward 5′- CAC GCG ATG CAA CAC CAC TCA GG -3′, Reverse 5′- GCA TGT CCC CGG GCT CAA AGA -3′; BSP: Forward 5′- TAC CGG CCA CGC TAC TTT CTT TAT -3′, Reverse 5′- GAC CGC CAG CTC GTT TTC ATC C -3′; Oc: Forward 5′- ACC CTG GCT GCG CTC TGT CTC T -3′, Reverse 5′- GAT GCG TTT GTA GGC GGT CTT CA -3′, Lef: Forward 5′-TCT CAA GGA CAG CAA AGC TC -3′, Reverse 5′- CAC TTG AGG CTT CAT GCA CAT -3′, Tcf: Forward 5′- ACA TGA AGG AGA TGA GAG CCA -3′, Reverse 5′- CTT CTT CTT TCC GTA GTT ATC -3′, Axin2: Forward 5′- ATG TGT GGA TAC GCT GGA CTT -3′, Reverse 5′- TTC TTG ATG CCA TCT CGT ATG -3′. Relative expression was quantified using the 2^−ΔΔCt^ method ^[@R72]^.

Gnas genotyping PCR {#S15}
-------------------

Primers used for PCR amplification of the conditional or mutant alleles were 5′- GAGAGCGAGAGGAAGACAGC -3′, 5′-TCGGGCCTCTGGCGGAGCTT -3′, 5′- AGCCCTACTCTGTCGCAGTC -3′. 100ng genomic DNA was PCR amplified (95°C -- 3min, 35 cycles (95°C -- 30sec, 62°C -- 45sec, 72°C -- 45sec), 72°C -- 8min, 15°C - forever) and we analyzed the PCR product on a 2% agarose gel with Ethidium Bromide to examine the presence of ∼400bp conditional allele band or ∼250bp mutant allele band.

In Situ Hybridization and X-gal staining {#S16}
----------------------------------------

Whole mount *in situ* hybridization and X-gal staining were performed using standard techniques ^[@R73]^.

Immunoblotting {#S17}
--------------

Immunoblotting was performed using standard techniques. The rabbit anti-Gli3 antibody kindly provided by Dr. Susan Mackem (NIH/NCI) and the rat anti-α-tubulin was purchased from Sigma. The antibodies for Gα~s~ (\#sc-55546, Santa Cruz Biotechnology), Creb (\#3360R, BioVision Incorporated), Phospho-Creb (\#06-519, Millipore), Gli2 (\#AF3635, R&D Systems), Gli1 (\#NB600-600, Novus Biologicals), Osx (\#ab22552, abcam), Oc (\#LS-C42094, , LifeSpan Biosciences), β-catenin (\#9562, Cell Signaling Technology), α/β-Tubulin (\#2148, Cell Signaling Technology) were used according to manufacturer\'s recommendations.

BMSC and SMP isolation and culture in osteogenic media {#S18}
------------------------------------------------------

We isolated BMSCs by flushing the bone marrow cavity of 6 week old mice and plating cells in Alpha-MEM, 20% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine. Prior to reaching confluence cells were infected with either Ad-Cre or Ad-GFP. Upon reaching confluence, cells were switch to osteogenic media \[DMEM, 10% lot-selected FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine, 10^-4^ M L-ascorbic acid 2-phosphate and 10 mM β-glycerol phosphate\] and cultured for the indicated time points. Subcutaneous skin tissue containing adipose deposits was removed under sterile conditions, and washed in PBS supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin on ice. The tissue was then minced, and digested with 1 mg/ml collagenase type I and 0.5%Trypsin in 0.1% BSA for 2 h at 37 °C . The digested tissue was centrifuged at 650 g for 10 min and the pellet was carefully collected after aspirating off the floating fat depots. After a second centrifugation at 650 g for 10 min, the cellular pellet was filtered through a 100-μm mesh filter to remove debris. The filtrate was cultured in 100-mm cell culture dishes under the same condition as the BMSCs.

Limb culture {#S19}
------------

We performed limb culture as described ^[@R74]^. BGJB culture media was supplemented with 0.2% bovine serum albumin (Sigma Aldrich) and Forskolin (Sigma Aldrich), IBMX (Sigma Aldrich), Cyclopamine (BIOMOL), Arsenic trioxide (ATO) (Sigma Aldrich) or GANT-58 (Tocris) at the indicated concentrations. Media was changed every alternate day.

Neural tube analysis {#S20}
--------------------

Analysis of neural tube patterning along the dorsal-ventral axis was done as described ^[@R75]^.

cAMP measurement {#S21}
----------------

To measure the cAMP levels in cells, We incubated the the cells in the presence of cAMP stabilizer, IBMX, for 30 minutes and then trypsinized and flash frozen the cells till cAMP measurement. We used the ACTOne cAMP fluorimetric ELISA kit (\#CB-80500-503, Codex BioSolutions Incorporated) per manufacturer\'s recommendations.

ATO, GANT-58 treatments {#S22}
-----------------------

We placed 50 mg of ATO in the bottom of a 50 mL conical tube and dissolved it with 1 mL of 1 N NaOH. 48 mL of PBS was then added to the tube and 0.82 mL of 1.2 N HCl was added to adjust the pH to 7.2. We dissolved GANT-58 in 20% DMSO and then diluted it with corn oil before injection. We weighed and then injected the pregnant mice with care to avoid injection into uterus.

GANT-58 cell treatments {#S23}
-----------------------

BMSCs were grown to confluence and placed in osteogenic media for 10 days with or without GANT-58 at the indicated concentrations.

Adenovirus injection and treatment {#S24}
----------------------------------

2 μl of the Cre recombinase or GFP adenovirus from SAIC, NCI, Frederick (∼10^10^ pfu/ml) were diluted in 100 μl PBS solution and injected into the subcutaneous region of the limbs of 4 weeks old mice. 6 weeks after injection, the mice were euthanized and the skins of the limbs were removed. Ectopic bone formation was analyzed by skeletal preparation and histological procedures. For the *R26SmoM2* mice, adenovirus injection was performed at 4 weeks of age and analysis was performed at 8 weeks of age.

Adenovirus cell culture treatment {#S25}
---------------------------------

The Cre recombinase or GFP adenovirus obtained from SAIC, NCI, Frederick (∼10^10^ pfu/ml) was diluted 1:2000 to infect cells. The dnPKA adenovirus was a kind gift from Chen-Ming Fan (∼10^10^ pfu/ml) and diluted to 1:300 to infect cells.

Statistics {#S26}
----------

Statistical significance was assessed using 2-tailed Student\'s *t* test for comparisons between 2 groups or by multivariate ANOVA analysis for multi-group comparisons. A *P* value less than 0.05 were considered significant. Data are presented as mean ± SD unless otherwise indicated.
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![Loss of *Gnas* in limb mesenchyme leads to HO\
(**a**, **b**) Representative alizarin red and alcian blue staining of forelimbs from wild-type littermate control (WT) and *Prx1-Cre;Gnas^f/−^* mutant mice at E17.5 (a) and P4 (b). Regions of initiating HO (a) and overt HO (b) are indicated (arrows). Scale bar, 1 mm. (c) Representative computed tomography (CT) scans of forelimbs from P20 WT littermate and *Prx1-Cre;Gnas^f/−^* mutant mice. (d) Representative alizarin red and alcian blue staining of hindlimbs from P20 WT littermate and *Prx1-Cre;Gnas^f/−^* mutant mice. A region of unmineralized Achilles tendon (left) and of ossified Achilles tendon (right) are indicated (arrowheads). Regions of HO are also indicated (arrows). Scale bar, 0.5 mm. (e, f) Longitudinal sections of the autopod of a P4 *Prx1-Cre;Gnas^f/f^* mouse counterstained with alcian blue and Sirius red and processed by Von Kossa staining (e) or by Osx immunohistochemistry (DAB, brown) (f). Regions of ectopic mineralization (black arrows) and chondrocyte hypertrophy and joint fusion (yellow arrows) are indicated (e), as are the brown nuclear staining of Osx-positive cells (black arrows) in interdigital regions of surrounding light-blued stained ossicles (f). The boxed interdigital regions in each panel are shown in higher magnification on the right. Scale bars, 0.2 mm (left), 0.05 mm (right).](nihms508101f1){#F1}

![Loss of *Gnas* in adult subcutaneous tissue leads to HO\
(a) Representative alizarin red and alcian blue staining of the *Gnas^f/f^* mice injected with either Ad-GFP or Ad-Cre virus in the subcutaneous regions (shown in [supplemental Fig. 3](#SD1){ref-type="supplementary-material"}). N=18. Extensive ectopic bone formation is indicated (arrow). Scale bar, 1 mm. (b) Histological analyses of ectopic bone formation shown in (a) by Osx and Oc immunohistochemistry (arrows) and Von Kossa staining (dark brown). Scale bar, 0.05 mm. (c, d) Representative Von Kossa staining of the ectopic bone (green arrows) in the subcutaneous (c) and the deep muscular regions (d) in the hindlimbs of *Gnas^f/f^* mice 12 weeks after Ad-Cre virus injection. H: hair follicle; M: muscle. Scale bars, 0.2 mm (c), 0.05 mm (d).](nihms508101f2){#F2}

![Removal of *Gnas* from mesenchymal progenitor cells upregulates Hh signaling *in vitro* and *in vivo*\
(a, b) Representative Von Kossa (a) or alizarin red staining (b) of Ad-Cre or Ad-GFP infected BMSCs from *Gnas^f/f^* mice after 10 days in osteogenic medium. (c) qRT-PCR analysis of osteoblast markers at day 7 following adenovirus infection (mean±SD; n=3; \* *p*=0.017 for Osx; 0.022 for Col1a1; 0.005 for Alpl; 0.003 for BSP; 0.003 for Oc). (d) Representative *in situ* hybridization performed on E14.5 forelimbs from the WT littermate control (left) and the *Prx1-Cre; Gnas^f/−^* embryos (right). Scale bar, 0.5 mm. (e) qRT-PCR analysis of RNA isolated from E14.5 forelimbs. Expression of *Gnas* and transcription targets of Hh pathway is shown (mean±SD; n=4; \* *p*=2.8×10^−5^ for Gnas; 0.012 for Ptch1; 0.036 for Gli1; 0.01 for Hhip). (f) qRT-PCR analysis of Hh pathway target genes in the BMSCs 2-3 days following Ad-Cre or Ad-GFP infection (mean±SD; n=3; \* *p*=1.1×10^−4^ for Ptch1; 0.001 for Gli1; 0.007 for Hhip).](nihms508101f3){#F3}

![Gα~s~ acts through cAMP and PKA to suppress Hh signaling\
(a) cAMP levels in SMPs from *Gnas^f/f^* mice as measured 3 days after adenovirus infection (mean±SD; n=3; \**p*=8.5×10^−5^). (b) PKA activity indicated by Phospho-Creb (P-Creb) protein levels in SMPs from *Gnas^f/f^* mice 5 days after adenovirus infection. (c) qRT-PCR assay of Hh target gene expression in SMPs from *Gnas^f/f^* mice 5 days after adenovirus infection (mean±SD; n=3; \**p*=4.4×10^−4^ for Ptch1; 2.4×10^−5^ for Gli1; 2.6×10^−6^ for Hhip). (d) Alizarin red staining of the SMPs from the *Gnas^f/f^* mice 14 days after the indicated treatment. (e) PKA activity indicated by P-Creb levels in SMPs from the *Gnas^f/f^* mice 5 days after the indicated treatment. (f) q-RT-PCR assay of Hh target expression in SMPs from the *Gnas^f/f^* mice that had been infected with adenovirus for 7 days and treated as indicated for 5 days (mean±SD; n=3; \**p*=2.1×10^−4^ for Ptch1; 8.7×10^−4^ for Gli1; 2.6×10^−4^ for Hhip). (g) PKA activity indicated P-Creb protein levels in WT SMPs infected by dnPKA adenovirus for 5 days. (h) qRT-PCR analysis of Hh target gene expression in WT SMPs infected by dnPKA adenovirus for 5 days (mean±SD; n=3; \**p*=0.001 for Ptch1; 2.1×10^−4^ for Gli1; 3.9×10^−4^ for Hhip). (i) qRT-PCR analysis of osteoblast differentiation marker expression in WT SMPs infected by dnPKA adenovirus for 5 days (mean±SD; n=3; \**p*=0.003 for Osx; 4.8×10^−4^ for Alpl). (j) Alizarin red staining of WT SMP cells infected by dnPKA adenovirus for 14 days.](nihms508101f4){#F4}

![Reducing Hh signaling inhibits HO *in vivo* and *in vitro*\
(a, b) Representative alizarin red and alcian blue staining of the limbs from E18.5 embryos with the indicated genotypes. Less severe HO, particularly in the hindlimb, is indicated (arrow) . In (b), the E18.5 embryos were from the pregnant female mice that had been injected with vehicles or the indicated Hh antagonists three times (E13.5, E15.5 and E17.5). Scale bars, 0.5 mm. (c) Alizarin red staining of the differentiating BMSCs from the *Gnas^f/f^* mice with the indicated treatment.](nihms508101f5){#F5}

![Hh signaling is activated in ectopic bone from POH individuals and activation of Hh signaling is sufficient to cause HO\
(a-c) GLI1 immunohistochemical staining of human samples. (a, b) Samples from a normal human subject. Scale Bars: 1 μm. (c) GLI1 expression in ectopic osteoblasts of the POH samples (arrows). Scale Bar: 1 μm. (d) Representative alizarin red and alcian blue staining of the limbs from the *R26SmoM2* mice injected with the Ad-GFP (left limb) or the Ad-Cre (right limb). Ectopic bone formation is indicated (arrows). N=8. (e) Alizarin red staining of the cultured SMP cells. (f) Schematic illustration showing the fundamental roles of Gα~s~ in bone formation and the mechanisms of *GNAS* mutations in bone disease (see text for more details). L: low, H: high, GOF: gain of function, LOF: loss of function.](nihms508101f6){#F6}
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